Regioselective Oxidative Arylation of Indoles Bearing <i>N-</i>Alkyl Protecting Groups: Dual C−H Functionalization via a Concerted Metalation−Deprotonation Mechanism
作者:Shathaverdhan Potavathri、Kyle C. Pereira、Serge I. Gorelsky、Andrew Pike、Alexis P. LeBris、Brenton DeBoef
DOI:10.1021/ja107159b
日期:2010.10.20
The most directmethod for synthesizing 2-arylindoles is oxidativecoupling of an arene with an indole. We have shown that both the activity and regioselectivity of this cross-coupling reaction are correlated with the acidity of the medium. This insight has been applied to predict the best conditions for the oxidative cross-coupling of N-alkylindoles, an important class of substrates that has heretofore
Compounds of formula I are provided
1
as well as pharmaceutically acceptable salts and esters thereof, wherein R
1
to R
8
, A, A
1
and n have the significance indicated in the specification.
提供了式I的化合物,以及其药用可接受的盐和酯,其中R1至R8,A,A1和n具有规范中指示的含义。
1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof
申请人:AVENTIS PHARMA S.A.
公开号:US20030153611A1
公开(公告)日:2003-08-14
1,3-Diarylprop-2-en-1-ones and derivatives, compositions containing them, manufacturing process and use. Substituted 1,3-diarylprop-2-en-1-ones with therapeutic activity may be used in oncology.
1-Aryl-3-(indol-5-yl) prop-2-en-1-ones, compositions containing them and use
申请人:Aventis Pharma S. A.
公开号:US20040229931A1
公开(公告)日:2004-11-18
1-Aryl-3-(indol-5-yl)prop-2-en-1-ones, compositions containing them and use thereof are disclosed and claimed. The present invention relates specifically to novel substituted 1-aryl-3-(indol-5-yl)prop-2-en-1-ones of formula (I) having a therapeutic activity, particularly, in oncology.
1
Wherein Ar, Y and R are as described herein.
1,3-DIARYLPROP-2-EN-1-ONES, COMPOSITIONS CONTAINING THEM AND USE THEREOF
申请人:Aventis Pharma S.A.
公开号:US20040147584A2
公开(公告)日:2004-07-29
Abstract of the Disclosure
1,3-Diarylprop-2-en-1-ones and derivatives, compositions containing them, manufacturing process and use. Substituted 1,3-diarylprop-2-en-1-ones with therapeutic activity may be used in oncology.